252 related articles for article (PubMed ID: 32915523)
1. Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA-REG OUTCOME.
Pellicori P; Ofstad AP; Fitchett D; Zeller C; Wanner C; George J; Zinman B; Brueckmann M; Lindenfeld J
ESC Heart Fail; 2020 Dec; 7(6):3401-3407. PubMed ID: 32915523
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
Verma S; Sharma A; Zinman B; Ofstad AP; Fitchett D; Brueckmann M; Wanner C; Zwiener I; George JT; Inzucchi SE; Butler J; Mazer CD
Diabetes Obes Metab; 2020 Jul; 22(7):1141-1150. PubMed ID: 32227432
[TBL] [Abstract][Full Text] [Related]
3. Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial.
Verma S; Leiter LA; Zinman B; Sharma A; Mattheus M; Fitchett D; George J; Ofstad AP; Kosiborod MN; Wanner C; Inzucchi SE
ESC Heart Fail; 2021 Aug; 8(4):2603-2607. PubMed ID: 34132492
[TBL] [Abstract][Full Text] [Related]
4. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial.
Fitchett D; Inzucchi SE; Zinman B; Wanner C; Schumacher M; Schmoor C; Ohneberg K; Ofstad AP; Salsali A; George JT; Hantel S; Bluhmki E; Lachin JM; Zannad F
ESC Heart Fail; 2021 Dec; 8(6):4517-4527. PubMed ID: 34605192
[TBL] [Abstract][Full Text] [Related]
5. Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.
Savarese G; Uijl A; Lund LH; Anker SD; Asselbergs F; Fitchett D; Inzucchi SE; Koudstaal S; Ofstad AP; Schrage B; Vedin O; Wanner C; Zannad F; Zwiener I; Butler J
J Card Fail; 2021 Aug; 27(8):888-895. PubMed ID: 34364665
[TBL] [Abstract][Full Text] [Related]
6. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Fitchett D; Butler J; van de Borne P; Zinman B; Lachin JM; Wanner C; Woerle HJ; Hantel S; George JT; Johansen OE; Inzucchi SE;
Eur Heart J; 2018 Feb; 39(5):363-370. PubMed ID: 29020355
[TBL] [Abstract][Full Text] [Related]
7. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.
Sharma A; Ofstad AP; Ahmad T; Zinman B; Zwiener I; Fitchett D; Wanner C; George JT; Hantel S; Desai N; Mentz RJ
JACC Heart Fail; 2021 Aug; 9(8):568-577. PubMed ID: 34325887
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial.
Monteiro P; Bergenstal RM; Toural E; Inzucchi SE; Zinman B; Hantel S; Kiš SG; Kaspers S; George JT; Fitchett D
Age Ageing; 2019 Nov; 48(6):859-866. PubMed ID: 31579904
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
10. Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
Verma S; Mazer CD; Inzucchi SE; Wanner C; Ofstad AP; Johansen OE; Zwiener I; George JT; Butler J; Zinman B
Diabetes Obes Metab; 2021 May; 23(5):1173-1181. PubMed ID: 33502090
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure.
Reifsnider OS; Kansal AR; Franke J; Lee J; George JT; Brueckmann M; Kaspers S; Brand SB; Ustyugova A; Linden S; Stargardter M; Hau N
ESC Heart Fail; 2020 Dec; 7(6):3910-3918. PubMed ID: 32909680
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial.
Böhm M; Slawik J; Brueckmann M; Mattheus M; George JT; Ofstad AP; Inzucchi SE; Fitchett D; Anker SD; Marx N; Wanner C; Zinman B; Verma S
Eur J Heart Fail; 2020 Jan; 22(1):126-135. PubMed ID: 31820559
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease - Implications for Clinical Practice.
Fitchett DH
Eur Endocrinol; 2018 Sep; 14(2):40-49. PubMed ID: 30349593
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
Butler J; Zannad F; Fitchett D; Zinman B; Koitka-Weber A; von Eynatten M; Zwiener I; George J; Brueckmann M; Cheung AK; Wanner C
Circ Heart Fail; 2019 Jun; 12(6):e005875. PubMed ID: 31163986
[TBL] [Abstract][Full Text] [Related]
16. Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.
Böhm M; Fitchett D; Ofstad AP; Brueckmann M; Kaspers S; George JT; Zwiener I; Zinman B; Wanner C; Marx N; Mancia G; Anker SD; Mahfoud F
J Hypertens; 2020 Sep; 38(9):1829-1840. PubMed ID: 32618884
[TBL] [Abstract][Full Text] [Related]
17. Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.
Hundertmark MJ; Agbaje OF; Coleman R; George JT; Grempler R; Holman RR; Lamlum H; Lee J; Milton JE; Niessen HG; Rider O; Rodgers CT; Valkovič L; Wicks E; Mahmod M; Neubauer S
ESC Heart Fail; 2021 Aug; 8(4):2580-2590. PubMed ID: 33960149
[TBL] [Abstract][Full Text] [Related]
18. The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.
Kaku K; Wanner C; Anker SD; Pocock S; Yasui A; Mattheus M; Lund SS
Diabetes Obes Metab; 2022 Apr; 24(4):662-674. PubMed ID: 34908223
[TBL] [Abstract][Full Text] [Related]
19. Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Coleman RL; Gray AM; Broedl Md UC; Fitchett D; George JT; Woerle HJ; Zinman B; Holman RR
Diabetes Obes Metab; 2020 Jul; 22(7):1151-1156. PubMed ID: 32115840
[TBL] [Abstract][Full Text] [Related]
20. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]